Castle Biosciences vs Fulgent Genetics
CSTL and FLGT side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CSTL and FLGT compare
Castle Biosciences is the larger company, worth 1.5 times as much as Fulgent Genetics ($1.0B against $679M).
Castle Biosciences grew revenue faster over the last twelve months (9.8% versus 4.7% for Fulgent Genetics).
Castle Biosciences keeps more of each dollar of sales as profit, with a net margin of −6.1% compared with −27.5% at Fulgent Genetics.
Castle Biosciences scores higher on the StockData Score (11 against 8 for Fulgent Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CSTL | FLGT |
|---|---|---|
| Size and price | ||
| Market cap | $1.0B | $679M |
| Share price | $33.79 | $24.66 |
| Change, 1 year | −3.0% | −15.2% |
| Change, 5 years | −28.9% | −73.8% |
| Beta (5Y) | 1.38 | 0.89 |
| Employees | 883 | 1,300 |
| StockData Score | ||
| Total score | 11 (better) | 8 |
| Valuation score | 2 | 3 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 3 (better) | 1 |
| Health score | 4 | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.7× | 2.1× (better) |
| P/B | 2.2× | 0.7× (better) |
| P/FCF | 260× | – |
| FCF yield | 0.38% (better) | −0.21% |
| Fair value | $34.71 | $46.08 |
| Margin of safety | 2.6% | 46.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 9.8% (better) | 4.7% |
| Revenue growth, 5Y average | 40.6% (better) | −5.2% |
| Profitability | ||
| Gross margin | 77.1% (better) | 33.8% |
| Operating margin | −7.4% (better) | −39.2% |
| Net margin | −6.1% (better) | −27.5% |
| FCF margin | 1.1% (better) | −0.42% |
| Return on equity | −4.9% (better) | −8.6% |
| Return on invested capital | −11.1% (better) | −12.0% |
| Financial health | ||
| Debt / equity | 0.02 | 0.00 (better) |
| Interest coverage | −51.2× (better) | −1307.9× |
| Current ratio | 5.28 | 5.34 (better) |
| Altman Z-score | 6.63 (better) | 5.18 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Buyback yield | – | 9.5% |
| Shareholder yield | 0.00% | 9.5% (better) |
| Ownership | ||
| Held by institutions | 89.5% | 57.0% |
| Held by insiders | 1.9% | 39.5% |
| Insider net buying, 12 months | −$18.3M | −$286K (better) |
| Short interest, % of float | 7.0% | 12.1% |
Go deeper
- CSTL stock overview
- CSTL income statement
- CSTL valuation and score
- FLGT stock overview
- FLGT income statement
- FLGT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.